Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib

Article Oncology

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Megan E. Daly et al.

Summary: This article provides evidence-based recommendations for the management of patients with stage III non-small-cell lung cancer (NSCLC). The recommendations were developed through a literature search and expert consensus, covering various aspects of evaluation, surgery, neoadjuvant and adjuvant approaches, and management of unresectable stage III NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy

Xiaoqian Zhai et al.

Summary: A novel ALK fusion partner (ALK-GCA) and its sensitivity to alectinib in lung cancer were reported, highlighting the importance of detecting fusion mutations and reporting their response to guide treatment.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer

Yan Hu et al.

Summary: This case report presents a successful case of resectable ALK-positive NSCLC treated with neoadjuvant alectinib achieving pathological complete response. It demonstrates the feasibility and efficacy of alectinib as neoadjuvant therapy for resectable ALK-positive NSCLC.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Letter Oncology

OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient

Xiaoqian Zhai et al.

LUNG CANCER (2021)

Add to Collection

Article Oncology

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Alessandro Leonetti et al.

Summary: The report describes a patient with stage IIIA ALK(+) NSCLC who received alectinib as neoadjuvant treatment and achieved major pathological response. The ALNEO study aims to further explore the activity and safety of alectinib as a neoadjuvant treatment strategy.

CLINICAL LUNG CANCER (2021)

Add to Collection

Article Oncology